International Journal of Research in Pharmacy and Pharmaceutical Sciences
www.pharmacyjournal.in
ISSN: 2455-698X
Received: 07-12-2025, Accepted: 06-01-2026, Published: 21-01-2026
Volume 11, Issue 1, 2026, Page No. 54-59

Integrating artificial intelligence across the drug discovery pipeline: Applications, challenges, and future prospects in pharmaceutical sciences

Dr. C Pandian[1*], Rathivadhana P[2], Reshma S[2], Sasi C[2], Navina S[2]
[1] Associate Professor, Department of Pharmaceutics, College of Pharmacy, Madurai Medical College, Madurai, Tamilnadu, India
[2] Department of Pharmaceutics, COP, MMC, Madurai, Tamilnadu, India

Abstract
Artificial Intelligence (AI) is rapidly transforming the pharmaceutical industry and has become a powerful catalyst for modern drug discovery and development. AI approaches such as machine learning, deep learning, natural language processing, and computer vision enable the analysis of large-scale genomic, proteomic, chemical, clinical, and real-world datasets that are beyond the capacity of conventional methods. AI accelerates target identification, de novo drug design, lead optimization, ADME prediction, toxicity assessment, and drug repurposing, thereby reducing cost, research timelines, and experimental failure rates. AI models have shown major benefits in rare disease diagnosis, personalized medicine and therapeutic target validation, while AI-driven synthetic data generation further improves target discovery when real sample availability is limited. AI-based quality control enables real-time and predictive defect detection in pharmaceutical manufacturing, minimizing waste and enhancing product reliability. Although challenges remain related to data standardization, model transparency, regulatory acceptance, ethics, and infrastructure requirements, AI holds strong potential to reshape the drug development pipeline. This review highlights the technological impact, evolving applications, advantages, limitations, and future prospects of AI in pharmaceuticals, establishing AI as a central driver toward faster, efficient, precise, and patient-centred drug discovery.

Keywords: Artificial intelligence, machine learning, drug discovery, ADME prediction, toxicity assessment, rare diseases, pharmaceutical quality control

Introduction

Artificial Intelligence (AI) has rapidly expanded in healthcare and the pharmaceutical industry over the last decade. AI refers to a branch of computer science focused on developing algorithms that simulate human cognitive functions such as learning, reasoning, and problem solving. It includes machine learning (ML), deep learning (DL), natural language processing (NLP), and computer vision (CV). AI is already assisting health care providers in disease diagnosis, screening, triage, risk analysis, surgery, clinical data analysis and is expected to show massive market expansion. Although research on healthcare AI has exponentially increased since 2000, real clinical implementation remains limited due to issues like dataset shift, overfitting, bias, and lack of generalizability, privacy and data sharing concerns, lack of algorithm transparency, high costs, workflow changes, and regulatory barrier [1, 2]. Despite these challenges, AI has huge potential to improve clinical decision making, enhance care processes and improve patient safety, but current level-1 evidence is still insufficient to support routine clinical use. In the pharmaceutical sector, AI is revolutionizing drug discovery and development which traditionally takes over 10–15 years and costs more than $2.6 billion to bring a new drug to market [3]. AI accelerates all stages of development: target identification and validation by analysing genomic, proteomic and clinical data; virtual screening of millions of compounds; lead optimization; molecule design using deep learning and GANs; prediction of ADME, toxicity and pharmacokinetics; NLP-based literature mining; improving clinical trial design, protocol optimization and patient recruitment; predicting treatment responses; drug repurposing; and post-marketing pharmacovigilance. AI enables faster, more accurate, and cost-effective selection of drug candidates and supports personalized medicine. However, for successful large-scale adoption, issues such as ethical concerns, data privacy, regulatory compliance, data standardization, transparency, interpretability of models, and collaboration between pharmaceutical scientists and data scientists must still be overcome [4, 5, 6].

Approaches

Machine Learning (ML) is a subfield of AI that enhances model accuracy by learning patterns from large datasets such as images, text, and human behavioural information. ML methods include supervised learning, unsupervised learning, and reinforcement learning for predictive modelling.

Deep Learning (DL), an advanced form of ML, uses multi-layered neural networks to handle complex computational tasks including autonomous driving, face recognition, and generative creation of images, music and videos. Natural Language Processing (NLP) focuses on enabling machines to interpret and process human language for applications such as sentiment analysis, language translation, chatbots, summarization and speech recognition [7]. Meanwhile, Computer Vision (CV) provides computers with the ability to understand and analyse visual content from images and videos, widely applied in medical diagnostics, industrial quality control and automation [8].

History

The adoption of AI in the pharmaceutical industry has evolved over several decades. Early conceptual foundations began in the 1950s–1960s with pioneers such as Alan Turing, John McCarthy, and Marvin Minsky, followed by the emergence of expert systems like DENDRAL in the 1970s–1980s, which applied rule-based logic for chemical structure prediction. In the 1990s, advancements in computational chemistry, QSAR modelling, and the growth of chemical databases led to the rise of cheminformatics, enabling virtual screening and early pattern recognition approaches in drug discovery. The completion of the Human Genome Project in 2003 ushered in the era of big data in genomics and proteomics, establishing bioinformatics as a key discipline where statistical learning, clustering, and machine learning models were used to identify biomarkers, disease targets, and pathway-level insights.

AI adoption accelerated significantly from the 2000s onwards due to increased computational power, larger datasets, and improved machine learning algorithms. Pharma industries began integrating AI for virtual screening, toxicity prediction, lead optimization, and target identification, supported by open-source chemical and biological databases such as CHEMBL and PubChem. From the mid-2010s, modern deep learning, generative AI, and NLP triggered a major transformation, allowing AI to design novel molecules, repurpose drugs, analyze complex biological networks, and accelerate development timelines. Companies like DeepMind, Insilico Medicine, Atomwise, and Benevolent AI have demonstrated rapid candidate identification, and during the COVID-19 pandemic, AI models supported rapid vaccine and therapeutic target discovery. The first AI-designed drug (DSP-1181) entering clinical trials in 2020 marked a significant milestone, proving that AI can move beyond supportive analysis to generating clinically viable drug candidates.

Today, AI continues to impact pharmacovigilance, personalized medicine, clinical prediction, and decision support, demonstrating real-world translation and value within pharmaceutical R&D [9].

Advantages

Artificial intelligence (AI) has created new opportunities for accelerating and enhancing the efficiency of drug discovery and development. By analysing vast, multidimensional datasets, AI enables faster identification of potential drug candidates, significantly reducing the time and cost associated with traditional experimental trials [10]. It improves drug design accuracy through predictive modeling and reliable data-driven analysis, surpassing conventional trial-and-error methods. AI demonstrates broad applicability across small molecule design, biologics, and therapeutic development, providing rapid insights for lead optimization. Moreover, by integrating chemical, biological, and clinical data, AI supports holistic models that expand the chemical space and facilitate the discovery of novel lead compounds. It also contributes to the advancement of gene editing and gene therapy. Overall, AI enhances productivity and cost-effectiveness in pharmaceutical R&D by prioritizing promising candidates and minimizing experimental failures [11].

Disadvantages

Despite its transformative potential, AI in pharmaceuticals faces several limitations and challenges. High-quality, standardized datasets remain essential yet difficult to obtain, affecting model reliability [12]. Model interpretability also poses a problem, as complex “black-box” algorithms hinder transparency, trust, and regulatory approval [13]. Regulatory uncertainty persists due to the lack of established guidelines for AI-based methodologies ensuring safety and efficacy [14]. Additionally, AI development demands expensive computing infrastructure and skilled professionals—resources limited in many countries, including India [15, 16]. Beyond technical and regulatory concerns, ethical and societal issues arise: AI cannot replicate human judgment, adapt through experience, or display creativity and emotional intelligence [17, 18]. Overreliance on automation may also lead to unemployment and reduced human engagement in scientific innovation [19].

Denovo Drug Design

De novo drug design involves creating entirely new molecular structures with desired biological activities using computational methods. Artificial intelligence (AI) enhances this process by predicting molecular properties, optimizing drug-likeness, and accelerating compound generation. AI-driven models, such as deep learning and generative algorithms, enable the design of novel ligands without prior templates. Depending on the approach, de novo design can be ligand-based, structure-based, or hybrid.

This integration of AI reduces time, cost, and improves the efficiency of drug discovery. Rule-Free Approaches in De Novo Drug Design Rule-free approaches in de novo drug design focus on generating novel molecules directly from desired properties without predefined construction rules. These methods rely heavily on generative deep learning models, such as recurrent neural networks (RNNs), variational autoencoders (VAEs), and generative adversarial networks (GANs). By learning molecular patterns from datasets expressed in SMILES format, these models can create new compounds with potential biological activity. The concept originated from the inverse QSAR approach, which used descriptor values to predict molecules with target properties. Rule-free methods offer high chemical diversity and creativity, though synthesizability remains a challenge compared to rule-based systems.

Mixed Approaches and the Role of AI in Rare Disease Diagnosis Combining rule-based and rule-free methods offers a balanced strategy, enabling both innovative molecular design and practical synthesis. Hybrid models integrate predefined chemical rules with AI-based generative design, ensuring drug-likeness and synthetic feasibility. Beyond drug discovery, artificial intelligence also plays a crucial role in rare disease diagnosis, where it helps analyze complex genetic, clinical, and imaging data. AI models can detect subtle patterns and correlations that are often missed by conventional diagnostic methods, reducing the time to diagnosis and improving patient outcomes in rare and complex disorders [20].

AI in Rare Diseases

AI plays an important role in rare disease (RD) diagnosis, which often takes up to 7 years due to symptom complexity and low prevalence. AI models such as NB, RF, XGBoost, CNN, AE, RNN and GAN can analyse genomic, imaging and clinical data to improve early detection and accuracy in RD identification. Studies have demonstrated high performance such as Fernández *et al*. using an InceptionV3-based CNN model achieving 95% accuracy in detecting tubers in MRI for tuberous sclerosis complex, and Founta using XGBoost and RF achieving 88.89% accuracy for ALS gene-based classification. However, ethical, legal and social considerations must be addressed, and AI medical devices require patient advocacy involvement. To ensure safe and sustainable use, AIMDs must be RD-aware throughout development, with multidisciplinary collaboration between clinicians, computer scientists and patient groups [21].

AI in Personalised Medicine

Personalized medicine aims to customize healthcare by considering each patient's genetic, environmental, and lifestyle characteristics. Artificial intelligence (AI) enhances this approach by analyzing complex datasets to predict drug responses and optimize treatment plans. In pharmacogenomics, AI algorithms can evaluate genetic variations to determine how patients metabolize specific drugs, such as antidepressants, improving prescription accuracy and minimizing adverse effects. Beyond genetics, AI integrates real-time data from wearable devices and mobile apps to assess physical activity, diet, and sleep patterns, offering a holistic view of patient health. By considering social, economic, and environmental determinants, AI enables clinicians to deliver truly individualized treatment strategies, improving therapeutic outcomes and reducing healthcare costs [9].

Ethical Considerations and Future Directions:

While AI promises transformative benefits in personalized medicine, it raises critical ethical and implementation challenges. Protecting sensitive genetic and health data is vital, requiring robust privacy frameworks and transparent algorithmic governance. Issues such as algorithmic bias, fairness across diverse populations, and the need for explainable AI (XAI) must be addressed to ensure ethical use and patient trust. Future advancements depend on integrating multi-omics data—genomics, proteomics, and metabolomics—through interdisciplinary collaboration. Overcoming barriers in scalability, interoperability, and clinician training is key for translating AI-driven research into clinical practice. Continued innovation in machine learning, combined with global data-sharing initiatives and regulatory oversight, will shape the next generation of AI-powered personalized medicine [22].

AI in Drug Toxicity Prediction

Drug toxicity prediction is a critical aspect of the drug development process, helping to ensure the safety and efficacy of new pharmaceutical compounds before clinical trials. Traditional toxicity testing relies on cell-based assays and animal studies, which are expensive and time-consuming. Artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has revolutionized this field by enabling rapid and accurate toxicity predictions based on molecular structures and biological data. Advanced AI tools such as eToxPred, DeepTox, TargeTox, and PrOCTOR analyze molecular descriptors and biological features to forecast toxic effects with high precision [23].

These models integrate information from extensive toxicity databases like TOXRIC, ICE, and DSSTox, which compile data on acute, chronic, and organ-specific toxicities across various species. By combining chemical, biological, and clinical data, AI-driven toxicity prediction significantly reduces experimental costs and accelerates safe drug discovery.

Research Advances and Organ-Specific Toxicity Prediction

Recent advances in AI-based toxicity research focus on predicting specific organ toxicities such as hepatotoxicity, nephrotoxicity, cardiotoxicity, and neurotoxicity. Deep learning models like ResNet18DNN and other neural network architectures have shown superior performance in predicting drug-induced liver injury (DILI) compared to traditional algorithms like random forests and gradient-boosting trees. Similarly, ML methods using molecular descriptors and physicochemical properties have been applied to predict kidney toxicity and cardiac side effects such as QT prolongation. For neurotoxicity, integrated models combining multiple fingerprints and classifiers, such as the MACCS-SVM model, have achieved high accuracy in identifying potential neurotoxic compounds. These AI approaches not only enhance prediction accuracy but also provide mechanistic insights into toxicity pathways, ultimately guiding safer drug design and minimizing late-stage clinical failures [24].

AI Driven Quality Control

AI-driven systems enable real-time defect detection by analyzing visual, sensor and process data instantly on the production line using computer vision and ML models. These systems identify subtle scratches, shape deformities, or irregularities traditional methods may miss, allowing immediate intervention and minimizing defective product progression. AI inspection can analyse thousands of tablets per minute, enabling rapid response and in-line production adjustments.

Beyond detection, predictive analytics based on historical production patterns allows forecasting potential defect occurrences in advance, optimizing yield and reducing downtime. AI systems continuously learn and adapt to new product designs and coating variations without major reconfiguration. They also handle complex pharmaceutical defects such as micro-cracks, particulate contamination, and improper fill levels and seal integrity in vials/ampoules as seen in Pfizer [26]. Overall, AI-driven QC significantly reduces waste, lowers cost, improves raw material utilization, avoids rework, and minimizes environmental impact by preventing machine failures and defective batch generation [25].

AI Driven Adme Prediction

Artificial Intelligence (AI) and Machine Learning (ML) have revolutionized ADME (Absorption, Distribution, Metabolism, and Excretion) prediction, a critical aspect of pharmacokinetics that governs a drug's efficacy and safety. Traditional experimental and QSAR-based approaches, though valuable, are often time-consuming, expensive, and limited in scalability. AI-driven models, by contrast, leverage large-scale datasets and molecular descriptors—such as lipophilicity, molecular weight, and topological polar surface area—to predict complex biological behaviors with remarkable accuracy. Techniques like Random Forest (RF), Support Vector Machine (SVM), and Light Gradient Boosting Machine (LightGBM) have achieved superior performance in predicting drug absorption and distribution, including parameters such as intestinal permeability and volume of distribution (Vd).

Deep learning models, especially Artificial Neural Networks (ANNs), further enhance predictive power by capturing intricate nonlinear relationships in data, proving particularly effective in modeling complex barriers like the blood-brain barrier (BBB). In metabolism and excretion prediction, AI has demonstrated exceptional ability to decode biochemical and physiological patterns that influence drug fate. Random Forest and SVM-based models have been successfully used to identify sites of metabolism (SOM) and predict metabolic stability, especially for cytochrome P450 (CYP450) enzymes. Moreover, advanced deep learning architectures such as Convolutional Neural Networks (CNNs) can analyze molecular graphs to reveal structural and electronic features responsible for enzymatic interactions.

Similarly, models like Gradient Boosting Machines (GBM) and RF effectively predict excretion profiles, including renal clearance, by integrating key physicochemical and transporter-related properties. Overall, AI-based ADME prediction offers a robust, efficient, and cost-effective framework for early drug optimization, minimizing experimental burden while enhancing the precision of pharmacokinetic assessments [27].

AI Powered Therapeutic Target Identification

Identifying suitable drug targets is crucial as it defines the biological mechanisms that can be modulated for therapeutic benefit. Machine learning models analyse genomic, proteomic, clinical and multi-omic datasets to identify and prioritize disease-linked targets. Although experimental and omic innovations have expanded rapidly, identifying actionable therapeutic targets remains challenging, and AI integration offers a promising solution. AI reveals hidden biological patterns not easily recognized by humans and contributes to biomarker identification, drug–target interaction prediction, pharmacokinetics prediction, indication prioritization, and clinical trial design. AI-derived drugs such as GS-0976, EXS-21546, and INS018_055 are already entering and showing success in clinical trials. AI-generated synthetic data supports target discovery when real patient samples are limited, especially in rare diseases, and also helps reduce dataset imbalance and bias.

Many AI-identified targets are now validated experimentally, such as novel ALS targets in Drosophila, KANK1 validation in human neurons, HDAC6 inhibition for cardiomyopathy, and CDK20 targeting for HCC. Deep learning platforms like Deep-DTnet further enable in silico discovery and repurposing of drugs showing therapeutic effects in animal models [28].

Comparison between Conventional Methods and AI Integrated Methods Drug Discovery and Development

The integration of Artificial Intelligence (AI) into drug discovery and development has significantly enhanced the efficiency and precision of conventional methods. Traditional drug discovery relies heavily on experimental screening and trial-and-error approaches, which are time-consuming, expensive, and have a high failure rate. In contrast, AI-driven models accelerate hit identification, lead optimization, and toxicity prediction by analysing vast chemical and biological datasets with high accuracy. Machine learning algorithms predict binding affinities, bioactivity, and pharmacokinetic properties, reducing the need for extensive laboratory testing. Moreover, AI assists in optimizing clinical trial design, patient recruitment, and real-time monitoring, ensuring faster and more reliable outcomes.

Overall, AI integration transforms the conventional pipeline into a data-driven, cost-effective, and time-efficient process, advancing the development of safer and more effective therapeutics [29, 30, 31].

Features	Conventional drug discovery	Ai integrated drug discovery
Time Required	10–15 years for a new drug	3–6 years reduction possible
Cost	$2–3 billion on average	Potentially 30–50% cost reduction
Target Identification	Manual, lab-based screening	AI analyzes biological databases, genomics & proteomics
Hit Identification	High-throughput screening (HTS) of thousands of compounds	AI predicts active molecules from large datasets
Lead Optimization	Iterative chemical modifications	AI uses QSAR models, predictive analytics to optimize faster
Preclinical Testing	Animal studies, in-*vitro* assays	AI predicts toxicity, bioavailability, metabolism before lab testing
Success Rate	Very low (1 in 5,000 compounds become a drug)	Improved by filtering unpromising candidates early
Data Handling	Manual interpretation of experimental data	AI handles big data, integrates omics data, literature, clinical trials
Personalized Medicine	Limited capability	AI enables drug tailoring to patient genetics and profiles
Repurposing Drugs	Serendipitous or trial-based	AI finds new uses for old drugs through pattern recognition
Adaptability & Learning	Rigid workflows	AI models improve with data (machine learning and deep learning)
Examples	Penicillin, Aspirin, traditional drug pipelines	Exscientia, Atom-wise, Benevolent-AI, DeepMind's AlphaFold

Future Scope of AI in Drug Discovery and Development

The future of Artificial Intelligence (AI) in drug discovery and development holds immense potential to revolutionize every stage of the pharmaceutical pipeline—from target identification to clinical trials and post-market surveillance. AI-driven automation and "self-driving" laboratories will enable continuous, autonomous experimentation, drastically reducing research time and human error. Advanced AI systems like DeepMind's AlphaFold are already transforming structural biology by accurately predicting protein folding, thus accelerating drug design against complex disease targets.

Furthermore, integration of multi-omics data through platforms like NVIDIA's Clara and the emergence of quantum AI are expected to enhance the precision of molecular simulations, biomarker discovery, and compound screening. These innovations will not only speed up drug discovery but also expand the scope of precision medicine, making therapies more targeted and effective. Looking ahead, AI will play a central role in areas such as digital twin modelling for personalized treatments, continuous manufacturing automation, and AI-powered pharmacovigilance systems that monitor drug safety in real-time. Federated learning will foster secure, collaborative research across global institutions while preserving data privacy. Additionally, AI-driven synthetic biology will enable the design of microbial systems for sustainable drug and vaccine production, reducing dependency on traditional chemical synthesis. Regulatory agencies are also expected to adopt predictive AI tools to streamline approval processes, improving efficiency without compromising safety standards. Collectively, these advancements position AI as a transformative force that will redefine the landscape of pharmaceutical innovation—making drug discovery faster, more efficient, and more patient-centred [32, 33].

Conclusion

In conclusion, Artificial Intelligence (AI) is reshaping the pharmaceutical industry by introducing unprecedented efficiency, precision, and innovation into every phase of drug discovery and development. Unlike traditional approaches, which are often time-consuming and resource-intensive, AI enables rapid identification of novel drug candidates, prediction of pharmacokinetic and toxicological profiles, and optimization of clinical trial processes. By integrating massive biological, chemical, and clinical datasets, AI empowers researchers to uncover hidden patterns and design more effective, safer therapeutics. Furthermore, its real-time analytical capabilities enhance decision-making, reduce failure rates, and significantly lower development costs—ultimately accelerating the delivery of life-saving medicines to patients worldwide.

Looking forward, the fusion of AI with genomics, quantum computing, and digital health technologies will further revolutionize precision medicine, allowing treatments to be tailored to individual genetic and physiological profiles. As regulatory bodies increasingly adapt to AI-driven innovations, the global healthcare ecosystem will benefit from faster approvals, more transparent oversight, and improved patient outcomes. The collaborative integration of AI across academia, industry, and government will be vital to ensure ethical use, data security, and equitable access to these advancements. Ultimately, AI stands not merely as a tool but as a transformative catalyst—ushering in a new era of intelligent, data-driven pharmaceutical research that promises to redefine the future of global healthcare.

Reference

1. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today,2019:24(3):773–780. doi: 10.1016/j.drudis.2018.11.014
2. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, *et al*. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov,2019:18:463–477. doi:10.1038/s41573-019-0024-5
3. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today,2018:23(6):1241–1250. doi: 10.1016/j.drudis.2018.01.039
4. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ,2016:47:20–33. doi: 10.1016/j.jhealeco.2016.01.012
5. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, *et al*. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater,2019:18(5):435–41. doi:10.1038/s41563-019-0338-z
6. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, *et al*. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol,2019:37(9):1038–40. doi:10.1038/s41587-019-0224-x
7. Campesato O. Artificial intelligence, machine learning, and deep learning. Mercury Learning and Information, 2020.
8. Ettalibi A, Elouadi A, Mansour A. AI and computer vision-based real-time quality control: a review of industrial applications. Procedia Computer Science,2024:231:212-20.
9. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, *et al*. Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. Pharmaceutics,2024:16(10):1328.
10. Ching T, Himmelstein DS, Beaulieu-Jones BK, *et al*. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface,2018:15(141):20170387.
11. Gupta SC, Sharma A, Mishra M, *et al*. Role of AI in drug discovery: applications and limitations. Curr Top Med Chem,2021:21(3):216-225.
12. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, *et al*. A guide to deep learning in healthcare. Nat Med,2019:25(1):24–9.
13. Samek W, Wiegand T, Müller KR. Explainable artificial intelligence: understanding, visualizing and interpreting deep learning models. arXiv preprint arXiv:1708.08296, 2017.
14. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med,2019:25(1):44–56.
15. Chen M, Mao S, Liu Y. Big data: A survey. Mobile Networks and Applications,2014:19(2):171–209.
16. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med,2019:380(14):1347–58.
17. Floridi L, Cowls J, King TC, Taddeo M. How to design AI for social good: Seven essential factors. Sci Eng Ethics,2020:26(3):1771–96.
18. Morley J, Machado C, Burr C, Cowls J, Taddeo M, Floridi L. The debate on the ethics of AI in health care: A reconstruction and critical review. Sci Eng Ethics,2020:26(3):1171–89.
19. Susskind R, Susskind D. The future of the professions: How technology will transform the work of human experts. Oxford: Oxford University Press, 2015.
20. Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. Expert opinion on drug discovery,2021:16(9):949-59.
21. Kitaoka Y, Uchihashi T, Kawata S, Nishiura A, Yamamoto T, Hiraoka SI, *et al*. Role and potential of artificial intelligence in biomarker discovery and development of treatment strategies for amyotrophic lateral sclerosis. International Journal of Molecular Sciences,2025:26(9):4346.
22. Okolo CA, Olorunsogo T, Babawarun O. A comprehensive review of AI applications in personalized medicine. Int J Sci Res

Arch,2024:11(01):2544-2549. doi:10.30574/ijsra.2024.11.1.0338
23. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug discovery and evaluation: safety and pharmacokinetic assays, 2024, 1461-98.
24. Zhang R, Wen H, Lin Z, Li B, Zhou X. Artificial Intelligence-Driven Drug Toxicity Prediction: Advances, Challenges, and Future Directions. Toxics,2025:13(7):525.
25. Ghelani H. AI-Driven quality control in PCB manufacturing: enhancing production efficiency and precision. Valley International Journal Digital Library,2024:12(10):1549-64.
26. Kothamali PR. Ai-powered quality assurance: Revolutionizing automation frameworks for cloud applications. Journal of Advanced Computing Systems,2025:5(3):1-25.
27. Sundeep K, Lavanya G. Artificial intelligence in drug discovery: Predicting ADME properties. Int J Innov Eng Res Manag,2022:9(6):430.
28. Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. Trends in pharmacological sciences,2023:44(9):561-72
29. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, *et al*. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals,2023:16(6):891.
30. Ocana A, Pandiella A, Privat C, Bravo I, Luengo-Oroz M, Amir E, *et al*. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomarker Research,2025:13(1):45.
31. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of deep learning in biomedicine. Mol Pharm,2016:13(5):1445-1454.
32. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med,2019:25(1):44–56.
33. Angelini M, Clancy CE, Tomaselli GF. AI for rare disease drug discovery: a paradigm shift. Nat Rev Drug Discov,2023:22(4):239–40.